These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 29556606)
1. Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data. Gaber R; Watermann I; Kugler C; Vollmer E; Perner S; Reck M; Goldmann T Rom J Morphol Embryol; 2017; 58(4):1175-1184. PubMed ID: 29556606 [TBL] [Abstract][Full Text] [Related]
2. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer. Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study. Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644 [TBL] [Abstract][Full Text] [Related]
4. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer. Hitij NT; Kern I; Sadikov A; Knez L; Stanič K; Zwitter M; Cufer T Clin Lung Cancer; 2017 May; 18(3):e187-e196. PubMed ID: 28089159 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870 [TBL] [Abstract][Full Text] [Related]
7. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821 [TBL] [Abstract][Full Text] [Related]
8. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry. Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812 [TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical detections of EGFR status in NSCLC]. Wang J; Liu C; Zhong D; Xu D; Ning C; Ma Q Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):212-8. PubMed ID: 25936885 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143 [TBL] [Abstract][Full Text] [Related]
11. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500 [TBL] [Abstract][Full Text] [Related]
12. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838 [TBL] [Abstract][Full Text] [Related]
13. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121 [TBL] [Abstract][Full Text] [Related]
14. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958 [TBL] [Abstract][Full Text] [Related]
16. Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies. Qu YG; Zhang Q; Pan Q; Zhao XD; Huang YH; Chen FC; Chen HL Int J Nanomedicine; 2014; 9():5771-8. PubMed ID: 25525358 [TBL] [Abstract][Full Text] [Related]
17. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618 [TBL] [Abstract][Full Text] [Related]
18. [Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma]. Liang ZY; Zeng X; Zhang J; Wu SF; Gao J; Liu TH Zhonghua Bing Li Xue Za Zhi; 2008 Oct; 37(10):654-9. PubMed ID: 19094482 [TBL] [Abstract][Full Text] [Related]